Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

18.44B

Market cap18.44B

Price-Earnings ratio

12.47

Price-Earnings ratio12.47

Dividend yield

—

Dividend yield—

Average volume

1.70M

Average volume1.70M

High today

$126.19

High today$126.19

Low today

$123.97

Low today$123.97

Open price

$124.89

Open price$124.89

Volume

816.74K

Volume816.74K

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

Seeking Alpha 2d

Eli Lilly’s Alzheimer’s drug cleared in Australia despite setback for Biogen

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, making it the country’s first amyloid-...

Analyst ratings

54%

of 37 ratings

Buy

45.9%

Hold

54.1%

Sell

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.